Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped

…, Y Bouhnik, D Laharie, JL Dupas, H Pillant, L Picon… - Gastroenterology, 2012 - Elsevier
BACKGROUND & AIMS: It is important to determine whether infliximab therapy can be safely
interrupted in patients with Crohn's disease who have undergone a period of prolonged …

Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial

…, JC Delchier, D Laharie, J Moreau, G Cadiot, L Picon… - Gastroenterology, 2006 - Elsevier
Background & Aims: The aim of this study was to evaluate the usefulness of short-term
infliximab combined with azathioprine (AZA) or 6-mercaptopurine (6-MP) in steroid …

Diabetogenic effect of streptozotocin in the rat during the perinatal period

B Portha, C Levacher, L Picon, G Rosselin - Diabetes, 1974 - Am Diabetes Assoc
The diabetogenic effect of streptozotocin was investigated in the rat during the fetal and
neonatal life. Streptozotocin was directly injected in the vitellin vein of the fetus or in the …

Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease

…, D Laharie, JL Dupas, H Pillant, L Picon… - Inflammatory bowel …, 2014 - academic.oup.com
Background Crohn's disease (CD)–associated dysbiosis could predispose patients to
relapse. Gut microbiota composition of patients from the prospective cohort study designed …

Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease

…, JM Gornet, C Baudry, S Koch, L Picon… - Clinical …, 2016 - Elsevier
Background & Aims Phase 3 trials have shown the efficacy of vedolizumab, which binds to
integrin α4β7, in patients with Crohn's disease (CD) or ulcerative colitis (UC). We …

Chemical diabetes in the adult rat as the spontaneous evolution of neonatal diabetes

B Portha, L Picon, G Rosselin - Diabetologia, 1979 - Springer
Injection of streptozotocin in newborn rats induced a severe diabetic syndrome on day 4
after birth, with acute hyperglycaemia and glycosuria. Over the next 3 weeks spontaneous …

Infliximab pharmacokinetics in inflammatory bowel disease patients

…, D Degenne, H Watier, L Picon… - Therapeutic drug …, 2008 - journals.lww.com
Infliximab, a chimeric monoclonal antibody, has profoundly modified the treatment of several
inflammatory diseases, but no satisfactory description of its pharmacokinetics is available …

Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization …

…, P Burtin, A Lortholary, Y Dumesnil, L Picon… - Journal of Clinical …, 1998 - ascopubs.org
PURPOSE A relationship between fluorouracil (5-FU) dose and response has been
previously shown in advanced colorectal cancer. In a previous study with 5-FU stepwise …

One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study

…, S Koch, S Viennot, A Aubourg, L Picon… - Alimentary …, 2017 - Wiley Online Library
Background We recently showed that vedolizumab is effective in patients with Crohn's
disease (CD) and ulcerative colitis (UC) with prior anti‐TNF failure in a multicentre …

[HTML][HTML] Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open …

…, N Ding, B Siegmund, G d'Haens, L Picon… - The Lancet …, 2023 - thelancet.com
Background The combination of infliximab and immunosuppressant therapy is a standard
management strategy for patients with Crohn's disease. Concerns regarding the implications …